Dutch Doctors Call for EU Evaluation of Cost Effectiveness of High Cost Orphan Drugs
Overview
Authors
Affiliations
A systematic review of moral reasons on orphan drug reimbursement.
Zimmermann B, Eichinger J, Baumgartner M Orphanet J Rare Dis. 2021; 16(1):292.
PMID: 34193232 PMC: 8247078. DOI: 10.1186/s13023-021-01925-y.
Kanters T, van der Ploeg A, Kruijshaar M, Rizopoulos D, Redekop W, Rutten-van Mlken M Orphanet J Rare Dis. 2017; 12(1):179.
PMID: 29237491 PMC: 5729274. DOI: 10.1186/s13023-017-0731-0.
Zelei T, Molnar M, Szegedi M, Kalo Z Orphanet J Rare Dis. 2016; 11(1):72.
PMID: 27259284 PMC: 4893267. DOI: 10.1186/s13023-016-0455-6.
Orphan drugs expenditure in the Netherlands in the period 2006-2012.
Kanters T, Steenhoek A, Hakkaart L Orphanet J Rare Dis. 2014; 9:154.
PMID: 25304026 PMC: 4195995. DOI: 10.1186/s13023-014-0154-0.
Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.
Hutchings A, Schey C, Dutton R, Achana F, Antonov K Orphanet J Rare Dis. 2014; 9:22.
PMID: 24524281 PMC: 3930763. DOI: 10.1186/1750-1172-9-22.